Resources
105 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 4/12/2024
This peer reviewed journal article OUD treatment and pregnancy outcomes among pregnant patients receiving OUD care through a telehealth addiction treatment program in the US. The patients identified in the study received buprenorphine or buprenorphine and naloxone treatment.
Posted 4/5/2024
This study assessed the associations between insurance status and 6-month retention of patients with opioid use disorder on telehealth platforms. Patients whose insurance paid for their care were most likely to still be receiving buprenorphine 6 months after starting treatment. Uninsured patients who paid cash were more likely to be in treatment at 6 months than people with insurance that did not cover their care. Findings showed an association between in-network insurance benefits and retention, which may affect the opioid crisis.
Posted 4/5/2024
The report Financing Peer Recovery Support: Opportunities to Enhance the Substance Use Disorder Workforce was prepared for the Substance Abuse and Mental Health Services Administration (SAMHSA) Center for Financing Reform and Innovation (CFRI) and provides background history of the development of Peer Recovery (PR), including an overview of the current landscape of PR Programs. This report also provides a description of the variation in peer recovery rates, supervision, credentialing, and substance use disorder vs mental health.
Posted 3/29/2024
The Centers for Disease Control and Prevention (CDC) has naloxone trainings and fact sheets available for clinicians. The trainings and fact sheets can help clinicians raise awareness about the benefits of naloxone by talking with patients and their family, friends, and caregivers.
Posted 3/10/2024 (updated 3/28/2024)
The Substance Abuse and Mental Health Services Administration's (SAMHSA) updated Overdose Prevention and Response Toolkit provides guidance to a wide range of individuals on preventing and responding to an overdose. It emphasizes harm reduction and access to treatment as essential aspects of overdose prevention.
Posted 1/19/2024 (updated 3/28/2024)
The FDA announced that the manufacturer of NARCAN 4 mg Nasal Spray products, Emergent BioSolutions, has extended the shelf-life of their product from 3 years to 4 years. This new extension of shelf-life was requested by the FDA to help prevent overdoses and reduce overdose-related deaths.
Posted 11/28/2023 (updated 3/28/2024)
Substance use is a major health issue among individuals in custody, and for these individuals, withdrawal from substances can be life-threatening. Jurisdictions have a pressing responsibility to save lives by implementing policies and protocol that align with legal, regulatory, and clinical standards related to appropriate withdrawal management. Recently released Guidelines for Managing Substance Withdrawal in Jails sets forth best clinical practices and actionable guidance for jails. This presentation discussed readiness for implementation, key components of implementation, and solutions for implementation in local communities and jails.
Learning Objectives:
-Assessed readiness for implementing a comprehensive and appropriate multidisciplinary approach to withdrawal management.
-Discussed action steps for building community support.
-Identified resources for training and technical assistance to implement the Guidelines.
Presenter:
Linda J. Frazier, B.S, M.A., RN, MCHES
Principal Consultant, Advocate for Human Potential, Inc.
Posted 10/23/2023 (updated 5/24/2024)
Using data from 77 harm reduction programs in 25 US states, researchers found that 12-15% of powder methamphetamine and powder cocaine also contained fentanyl although the prevalence varied geographically. Prevalence of fentanyl in crystal methamphetamine and crack cocaine was lower. Heroin and xylazine were also found in unregulated stimulants. Xylazine reduced the ability to detect fentanyl.
Posted 9/28/2023 (updated 3/27/2024)
The University of Vermont Center on Rural Addiction (UVM CORA), the University of Rochester, and the Fletcher Group have conducted an online survey assessing SUD stigma (including stigmatizing language), treatment needs and barriers, and concerns through the perspectives of rural, RCORP-affiliated practitioners. The data report explores the findings of the survey, including practitioner recommendations on improving access to OUD treatment.
Posted 7/31/2023 (updated 3/26/2024)
At the end of July 2023, the U.S. Food and Drug Administration approved a second over-the-counter naloxone nasal spray product, RiVive. The agency who received the approval to manufacture the product, Harm Reduction Therapeutics, does not yet have a timeline of availability and decision on pricing.